The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
NCT ID: NCT02395640
Last Updated: 2021-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
438 participants
INTERVENTIONAL
2015-03-31
2021-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XELOX
oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
Oxaliplatin
Capecitabine
1000mg/m2 po d1-14
EOX
Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
Epirubicin
50mg/m2 ivgtt d1
Oxaliplatin
Capecitabine
1000mg/m2 po d1-14
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epirubicin
50mg/m2 ivgtt d1
Oxaliplatin
Capecitabine
1000mg/m2 po d1-14
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1
* an Eastern Cooperative Oncology Group performance status of 0 to 2
* adequate renal, hepatic, and hematologic function
Exclusion Criteria
* uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting illness or previous or concurrent cancer
* accumulated dose of Epirubicin exceeds 300mg/m2
* HER2 positive and willing to use trastuzumab
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Weijian Guo
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, Zhang XW, Liu X, Wang CC, Zhang W, Ying JE, Wu J, Yang L, Qin YR, Luo JF, Zhao XY, Li WH, Zhang Z, Qiu LX, Geng QR, Zou JL, Zhang JY, Zheng H, Song XF, Wu SS, Zhang CY, Gong Z, Liu QQ, Wang XF, Xu Q, Wang Q, Ji JM, Zhao J, Guo WJ. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond). 2022 Apr;42(4):314-326. doi: 10.1002/cac2.12278. Epub 2022 Feb 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDZL-EXELOX
Identifier Type: -
Identifier Source: org_study_id